Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference
May 17, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, China, May 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical...
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
May 03, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
Primary endpoint of change from baseline on adapted Mayo Score for CBP-307 0.2 mg once-daily, orally administered dose showed a numerical improvement, but did not achieve statistical significance...
Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update
March 31, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
- Global Phase 3 Trial of CBP-201 in Moderate-to-Severe Atopic Dermatitis Expected to Commence in H2 2022 -- Topline Phase 2 CBP-307 Results in Moderate-to-Severe Ulcerative Colitis Expected to Be...
Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer
March 01, 2022 08:00 ET
|
Connect Biopharma Holdings Limited
CMO appointment to propel Connect through clinical milestones across solid pipeline of inflammatory disease therapies in development SAN DIEGOand TAICANG, China, March 01, 2022 (GLOBE NEWSWIRE) --...
Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
February 09, 2022 07:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, China, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical...
Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference
January 24, 2022 07:00 ET
|
Connect Biopharma Holdings Limited
—Data provides detailed results, with achievement of both primary and key secondary end points and demonstrating significant improvements in skin clearance, disease severity, and itch compared to...
Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis
January 05, 2022 07:00 ET
|
Connect Biopharma Holdings Limited
—Phase 2b trial previously reported achievement of both primary and key secondary end points, demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo— ...
Connect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201
January 04, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, China, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical...
Connect Biopharma Expands Executive Leadership Team with Hire of Chief Financial Officer
November 22, 2021 08:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage...
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
November 19, 2021 08:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage...